Canaccord Genuity Initiates Coverage On Tandem Diabetes Care with Buy Rating, Announces Price Target of $57
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity has initiated coverage on Tandem Diabetes Care (NASDAQ:TNDM) with a Buy rating and a price target of $57, as announced by analyst William Plovanic.
August 08, 2024 | 10:48 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity has initiated coverage on Tandem Diabetes Care with a Buy rating and a price target of $57.
The initiation of coverage with a Buy rating and a specific price target of $57 by a reputable analyst is likely to positively impact the stock price of Tandem Diabetes Care in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100